b'As Dr. Von Hoff deservingly steps into retirement, the legacy he leaves behind in cancer research is nothing short of extraordinary.His treatment began with three months of combination chemotherapy developed at the Research Institute, which has now become the standard of care in the National Comprehensive Cancer Network guidelines. He now has no evidence of cancer.As Dr. Von Hoff deservingly steps into retirement, the legacy he leaves behind in cancer research is nothing short of extraordinary. His relentless pursuit of cures, combined with his compassion for his patients, has dedication to science and compassionate care, withtransformed the landscape of cancer treatment and given a sense of urgency and impatience with bureaucracy,hope to countless individuals, when often they had none.fit my own vision for a unique new hybrid clinical research institute that combined the best of leadingSoon, his lab will no longer echo with his presence, but the academic institutions and community healthcarebreakthroughs he championed will continue to shape the while pruning the challenging aspects of each. future of cancer research and care for generations to come.In 2021, Dr. Michael Gordon, chief medical officerIn the hearts of his colleagues, patients and the entire at the HonorHealth Research Institute, heard themedical community, Dr. Von Hoff will always be very words he had delivered to his patients manyremembered as a trailblazera visionary whose work times before with a new perspective. You havebrought us closer to conquering one of humanitys pancreatic cancer. greatest challenges. His impact is immeasurable, and his legacy will endure, lighting the way for future researchers Armed with his knowledge and circle of colleagues, ledand physicians.by Dr. Von Hoff, he had access to the latest research, clinical trials and expert advice in the country. And for that, we celebrate and thank you, Dr. Von Hoff!HonorHealth Foundation Magazine 15'